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Abstract 
Prior studies using exploratory factor analysis provide evidence that negative 
symptoms are best conceptualized as 2 dimensions reflecting diminished motivation 
and expression. However, the 2-dimensional model has yet to be evaluated using more 
complex mathematical techniques capable of testing structure. In the current study, 
network analysis was applied to evaluate the latent structure of negative symptoms 
using a community-detection algorithm. Two studies were conducted that included 
outpatients with schizophrenia (SZ; Study 1: n = 201; Study 2: n = 912) who were rated 
on the Brief Negative Symptom Scale (BNSS). In both studies, network analysis 
indicated that the 13 BNSS items divided into 6 negative symptom domains consisting 
of anhedonia, avolition, asociality, blunted affect, alogia, and lack of normal distress. 
Separation of these domains was statistically significant with reference to a null model 
of randomized networks. There has been a recent trend toward conceptualizing the 
latent structure of negative symptoms in relation to 2 distinct dimensions reflecting 
diminished expression and motivation. However, the current results obtained using 
network analysis suggest that the 2-dimensional conceptualization is not complex 
enough to capture the nature of the negative symptom construct. Similar to recent 
confirmatory factor analysis studies, network analysis revealed that the latent structure 
of negative symptom is best conceptualized in relation to the 5 domains identified in 
the 2005 National Institute of Mental Health consensus development conference 
(anhedonia, avolition, asociality, blunted affect, and alogia) and potentially a sixth 
domain consisting of lack of normal distress. Findings have implications for identifying 
pathophysiological mechanisms and targeted treatments. 
 
Introduction 
Negative symptoms have been considered a core symptom of schizophrenia (SZ) since 
the earliest descriptions of the disorder.1,2 Factor analytic studies are consistent with 
this notion, indicating that negative symptoms are a dimension of psychopathology that 
is separate from other symptoms associated with psychotic disorders (eg, positive, 
disorganization).3–5 This early factor analytic evidence led the field to conceptualize 
negative symptoms as a unidimensional construct. However, when studies evaluated 
the factor structure of items within negative symptom scales alone, there was consistent 
evidence that negative symptoms were multidimensional. The majority of studies 
provide evidence for 2 distinct dimensions reflecting diminished motivation and 
pleasure (MAP: anhedonia, avolition, asociality) and diminished expressivity (EXP: 
blunted affect, alogia).6 The 2-factor structure has been observed across a variety of 
scales, including the Scale for the Assessment of Negative Symptoms 
(SANS),7 Schedule for the Deficit Syndrome,8–10Clinical Assessment Interview for 
Negative Symptoms (CAINS),11,12 and Brief Negative Symptom Scale 
(BNSS).13 Translated versions of these scales have also supported a 2-factor structure, 
suggesting that these dimensions are not culturally bound.14–17 Collectively, these 
findings have led the field to shift away from a unidimensional conceptualization, in 
favor of a 2-dimensional conceptualization of negative symptoms.18 
However, it is unclear whether the widespread adoption of the 2-dimensional structure 
is fully statistically or theoretically justified. Prior studies have primarily relied on 
exploratory factor analysis (EFA), which is ideal for generating hypotheses regarding 
how many dimensions may be present; however, these analyses are not capable of 
actually testing competing models regarding the number of dimensions that exist 
within the negative symptom construct unless formal fit indices are evaluated. To date, 
such indices have not been adopted when evaluating negative symptom structure via 
EFA. Studies using confirmatory factor analysis (CFA) can also apply model fit 
statistics to test competing models regarding the structure of negative symptoms based 
on theory. However, few CFAs have been conducted on negative symptom scales, and 
those that have been published do not strongly support the 2-dimensional structure. For 
example, 2 studies attempted to validate the 2-factor structure using Korean19 and 
Chinese20 translations of the CAINS. Both concluded that the CAINS was best fit by a 
2-factor structure, with dimensions reflecting MAP and EXP. However, the model fit 
statistics for the 2-factor model in both of these studies did not exceed common 
conventions for a model to be considered a good fit. In addition, the incorporation of 
modification indices to account for this poor fit in an exploratory manner flagged many 
misspecified residual covariances, suggesting that the 2-factor model should not have 
been supported. Similar findings were reported by a CFA study evaluating the 2-
dimensional model in first episode patients who were rated on the SANS, which also 
found that model statistics fell below threshold for good fit for a 2-factor EXP/MAP 
model.21 
Two recent CFA studies suggest that the failure to support the 2-dimension model may 
be because this model does not capture the complexity of negative symptoms and there 
may be additional dimensions of relevance.22,23 Strauss et al22 used CFA to evaluate the 
latent structure of the SANS,24 BNSS,25 and CAINS.12 Four CFA models were 
examined. The first was a unidimensional model, which considered whether all items 
best reflect a single latent negative symptom construct. The second was the 2-
dimensional model identified in prior EFA studies,7,11–17 reflecting EXP and MAP 
factors. The third model was a 5-factor model that specified 1 factor for each of the 5 
domains identified in the 2005 National Institute of Mental Health (NIMH) consensus 
development conference26: anhedonia, avolition, asociality, blunted affect, and alogia. 
The fourth model was a hierarchical model with 2 second-order factors reflecting EXP 
and MAP, as well as 5 first-order factors reflecting the 5 consensus domains. Results 
were consistent across all 3 scales/studies. The 1- and 2-factor models provided poor 
fit for the data. The 5-factor and hierarchical models provided excellent fit, with the 5-
factor model outperforming the hierarchical model. In a follow-up study,23 we 
evaluated the validity and cross-cultural invariance of the 5-factor model reported by 
Strauss et al22 The 4 aforementioned models were evaluated across 5 cross-cultural 
samples, with a total n = 1678 (location/language): Italy/Italian, Spain/Spanish, 
China/Chinese, Switzerland/German, and United States/English. Results replicated the 
original study,22 indicating that 1- and 2-factor models provided poor fit for the data, 
but 5-factor and hierarchical models provided excellent fit. Again, the 5-factor model 
mathematically outperformed the hierarchical model. It is important to clarify that good 
fit for the hierarchical model is not simply further support for the 2-dimensional 
conceptualization. This is because MAP and EXP are secondary dimensions in these 
hierarchical models and the 5 factors are primary. Because primary dimensions are the 
ones directly influencing ratings of all negative symptoms in these hierarchical models, 
this suggests that the 5 domains, not the MAP/EXP dimensions, are most fundamental 
and best account for negative symptom structure. 
Support for the 5-factor model across all 3 of the most current negative symptom 
scales22 and across a diverse range of cultures and languages23 in large representative 
samples raises the possibility that the recent trend toward conceptualizing negative 
symptoms in relation to the MAP and EXP dimensions18 does not capture the 
complexity of the construct, which is best represented by the 5 NIMH consensus 
domains. Clarifying the latent structure of negative symptoms is important because 
EFA studies supporting the 2 factors have been influential, informing how researchers 
search for pathophysiological mechanisms of negative symptoms27–29and how 
pharmaceutical companies have recently been approaching targeted treatment 
development.30 The current focus on the 2 factors precludes the identification of 
pathophysiological mechanisms or treatment effects that are specific to the 5 domains. 
Indeed, there is some preliminary evidence for distinct pathophysiological correlates 
of individual negative symptom domains,31 suggesting that further investigation is 
warranted. 
To further evaluate the latent structure of negative symptoms, the current study applied 
an alternate mathematical approach, network analysis, to objectively determine the 
optimal number of negative symptom domains on the BNSS. Network analysis is a 
mathematical method used to evaluate complex systems, focusing on the 
interrelatedness of system components, which is ideal for estimating latent structure of 
a construct. Rather than examining each symptom individually as one effect of a causal 
disorder, network analysis takes into account the interaction between each symptom 
and every other symptom, such that there is no examination of one symptom without 
consideration for the influence of all others.32 Few studies have applied network 
analysis to evaluate questions related to psychotic disorders. Prior studies have 
primarily focused on macroscopic network properties, such as network density and 
characteristic path length, which provide information about the collective properties of 
the network as a whole. Or they have investigated microscopic network properties 
using various centrality measures that indicate how individual nodes in the network 
interact. These approaches were ideal for answering the questions at hand, such as 
identifying which environmental factors influence the emergence of psychotic 
symptoms,33 which symptom interactions lead to treatment resistance vs 
responsiveness,34 and which psychological processes are most central to good vs poor 
functional outcomes in the community.35 To evaluate the question of interest in the 
current study (ie, the structure of negative symptoms), we focused on mesoscopic 
network properties, which are ideal for determining the number of dimensions within 
a construct. Specifically, a community detection metric was applied, which determines 
how different subsets of nodes (ie, BNSS items) in the network are clustered together. 
The nodes that belong to one “community” (ie, negative symptom domain) tend to have 
a stronger connection with each other whereas having a weaker connection with the 
nodes in other communities. This notion of communities of symptoms is similar to 
symptom cluster analysis where a cluster of symptoms is identified using statistical 
analyses. However, symptom cluster analysis only focuses on the interdependency of 
symptoms within one cluster, whereas community detection network analysis 
evaluates how clusters of symptoms interact with each other, to evaluate whether 
dimensions identified are distinct. Importantly, this network-based approach is not 
subject to several limitations inherent to CFA (eg, underestimating the number of 
factors when the correlations between factors are high and when sample size is small) 
and produces more reliable estimates of latent structure based on heuristic approaches. 
Network analysis therefore provides an approach that is complementary with CFA, but 
not redundant, as these 2 analyses can sometimes yield different results.34,36 
Data from 2 studies were analyzed using network analysis to evaluate the latent 
structure of negative symptoms. The first study included an American sample of 
outpatients with SZ (n = 201), and the second included a larger validation sample of 
SZ outpatients from the Italian national study (n = 912). On the basis of the results of 
recent CFAs supporting a 5-factor structure of negative symptoms,22,23 it was 
hypothesized that the community detection network analysis parameter would indicate 
that the 13 BNSS items cluster into 5 distinct communities corresponding to the 2005 
NIMH consensus domains: anhedonia, avolition, asociality, blunted affect, and alogia. 
In addition, it was hypothesized that the BNSS lack of normal distress item would 
produce a sixth community that would be separate from the 5 consensus domains. 
Although not part of the 5 NIMH consensus domains, lack of normal distress has been 
consistently demonstrated to be part of the negative symptom construct.37 Using CFA, 
the lack of normal distress item was found to load on all 5 of the consensus domains, 
but not highly on any specific domain, potentially indicating that it belongs on a 
separate dimension or is not part of the negative symptom construct.23 Given the 
potential for CFA to underestimate the true number of domains in a construct when the 
correlations between factors are high, network analysis provides a novel means of 
testing whether lack of normal distress might represent a sixth domain. 
Methods 
Participants 
Study 1. 
Participants included 201 outpatients meeting Diagnostic and Statistical Manual of 
Mental Disorders 4th edition (DSM-IV)38 criteria for SZ or schizoaffective disorder. 
Patients were recruited from 2 sites: (1) the outpatient research clinics at the Maryland 
Psychiatric Research Center and community mental health clinics in the Baltimore 
metropolitan area (n = 146); (2) the State University of New York at Binghamton, 
including community outpatient mental health clinics in upstate New York (n = 55). 
All patients were evaluated during periods of clinical stability as determined by a 
minimum of 4 weeks of consistent medication dose and type. Consensus diagnosis was 
established via a best estimate approach based on psychiatric history and subsequently 
confirmed using the Structured Clinical Interview for DSM-IV (SCID39). The study 
was approved by the ethics committees of each institution. 
The sample was on average 41.6 (12.1) years of age and had 13.2 (2.7) years of parental 
education; 72.6% were male; and 60.7% were Caucasian, 31.8% African-American, 
0.5% Hispanic, 1.5% Asian, 1.0% American Indian/Alaskan Native, and 4.5% Bi-
racial. Eighty-nine percent of the sample was prescribed an antipsychotic medication 
(5.0% first generation, 75% second generation, 9% both, 11% stably unmedicated). 
Study 2. 
Participants included 912 outpatients from the Italian National Study who were 
recruited from 26 Italian University psychiatric clinics in the Italian network for 
Research on Psychoses.40 Participants were 18–65 years of age and met DSM-
IVcriteria for SZ, which was confirmed with the SCID. Exclusion criteria were history 
of head trauma with loss of consciousness, history of moderate-to-severe mental 
retardation or neurological diseases, history of alcohol and/or substance abuse in the 
last 6 months, current pregnancy or lactation, inability to provide informed consent, 
and treatment modifications and/or hospitalization due to symptom re-exacerbation in 
the last 3 months. Participants had a minimum of 3 months of clinical stability as 
defined by no hospitalization due to symptom exacerbation, and no change in 
pharmacological treatment (type of drug or dose). The study was approved by the ethics 
committees of the local institutions. 
The sample was on average 40.1 (10.7) years of age, had 11.7 (3.4) years of education, 
69.8% were male, and 97% were prescribed an antipsychotic medication (14.1% first 
generation, 69.1% second generation, 13.8% both, 3% stably unmedicated). 
Procedures 
In both studies, the BNSS25 was administered as part of larger protocols. Prior to the 
start of the study, raters at each site were trained via an in-depth review of the BNSS 
manual, workbook, and scoring procedures. Raters were required to meet minimum 
reliability standards (inter-rater agreement ≥0.80) on gold-standard training videos 
prior to conducting assessments. All raters had a bachelor’s degree or higher and 1 or 
more years of clinical experience. 
Measures 
Brief Negative Symptom Scale. 
The BNSS20 is a 13-item negative symptom rating scale designed in response to 
recommendations from the 2005 NIMH consensus development conference.26 The 
BNSS includes 6 subscales: anhedonia, asociality, avolition, blunted affect, alogia, and 
lack of normal distress. All items are rated on a 7-point (0–6) scale, with anchors 
generally ranging from absent (0) to severe.6 It has demonstrated excellent 
psychometric properties in the original and translated versions.17,40–46 
Data Analysis 
Analyses were conducted using Python (NetworkX package) and MATLAB. Network 
analysis was used to detect the optimal number of communities among the 13 BNSS 
items. Complex networks, such as symptom networks in psychiatric disorders, tend to 
divide into modules (ie, communities). The strength of division of a network into 
modules is called modularity. Community detection is a problem of finding maximal 
modularity in the networks. Higher modularity of a network is an indication of dense 
connections within modules and sparse connections between nodes from different 
modules. In this study, a community detection algorithm was applied to the BNSS 
network for determining the number of clusters that the 13 BNSS items divided into. 
The BNSS symptom network was constructed using the association between BNSS 
variables calculated using mutual information (MI). MI is a simple method to calculate 
both linear and nonlinear relationship between variables using the following equation: 
 
 
 
  
Results 
Study 1 
Figure 1 displays a topographic map of the community detection findings resulting 
from network analysis. As shown in figure 1A, the 13 BNSS items divided into 7 
communities reflecting avolition, asociality, blunted affect, alogia, lack of normal 
distress, anhedonia intensity of pleasure, and anhedonia frequency of pleasure. 
Separation of these communities was demonstrated statistically by estimating the 
distribution of a quality function for randomized networks. Results indicated that each 
of the communities was significantly larger than communities of the same size detected 
in randomized networks, suggesting that the probability of identifying each community 
is greater than chance (see table 1). 
 
Fig. 1. 
 Fig. 1. Network analysis community detection topographic map. The nodes in the network represent the 13 
Brief Negative Symptom Scale (BNSS) items; the node colors represent detected communities by the Louvain 
method; and the edge width represents the strength of the MI value. BNSS items: 1 = intensity of pleasure 
during activities; 2 = frequency of pleasurable activities; 3 = intensity of expected pleasure from future 
activities; 4 = lack of normal distress; 5 = asociality behavior; 6 = asociality internal experience; 7 = avolition 
behavior; 8 = avolition internal experience; 9 = facial expression; 10 = vocal expression; 11 = expressive 
gestures; 12 = quantity of speech; 13 = spontaneous elaboration. The 6 negative symptom domains identified 
by the network analysis are: anhedonia = BNSS items 1–3; lack of normal distress = 4; asociality = 5–6; 
avolition = 7–8; blunted affect = 9–11; alogia = 12–13. (A) American Sample (Study 1: n = 201); (B) Italian 
Sample (Study 2: n = 912). For color, please see the figure online. 
Study 2 
Results obtained for the Italian national sample largely replicated those of the 
American sample (see figure 1B). The BNSS items divided into 6 communities 
reflecting anhedonia, avolition, asociality, blunted affect, alogia, lack of normal 
distress. Unlike Study 1, the 3 anhedonia items fell into 1 community, rather than 
separate communities for intensity and frequency. The quality function indicated that 
each of the 6 communities was significantly larger than communities of the same size 
detected in randomized networks (see table 1). 
To evaluate replicability of the networks in both studies, we randomly eliminated 5%, 
10%, 20%, 30%, and 40% of the cases and repeated the network analysis. This 
approach resulted in the same community structure. We also evaluated whether 
alternate community detection methods produced comparable results to the Louvain 
method, including the Fast Newman, Danon, and Martelot’s methods.49–51 These 
methods all led to results supporting the 5 domain structure in both American and 
Italian samples, although there were slight differences in whether item 2 produced its 
own community or aligned with items 1 and 2 to produce an aggregate anhedonia 
community (see Supplementary Materials). 
Discussion 
The current study used network analysis to evaluate the latent structure of negative 
symptoms across 2 experiments with large samples of outpatients with SZ. Findings 
were largely consistent across both studies. In Study 1, the community detection 
method revealed 7 distinct communities of symptoms that the 13 BNSS items fell into 
avolition, asociality, blunted affect, alogia, lack of normal distress, anhedonia intensity 
of pleasure, and anhedonia frequency of pleasure. In Study 2, 6 communities were 
detected, reflecting avolition, asociality, blunted affect, alogia, lack of normal distress, 
and anhedonia. The 3 anhedonia items fell into a single community, rather than 
separate communities for intensity and frequency in Study 2. We doubt these 
differences in the functioning of item 2 are meaningful given that in both the American 
and Italian samples, alternative network methods presented in Supplementary 
Materials (Fast Newman, Danon, and Martelot’s methods) indicated that item 2 
sometimes clustered with items 1 and 3 and at other times formed its own community. 
Despite these minor differences across samples and network methods, these findings 
are consistent with the results of 2 recent CFA papers.22,23 These papers found that 
1- and 2-factor models of negative symptoms were a poor fit, whereas a 5-factor model 
provided an excellent fit. Collectively, results from these 2 CFA papers and the current 
network analysis findings support the 5-domain conceptualization of negative 
symptoms, and indicate that conclusions regarding latent structure are not scale 
dependent, culturally restricted, or specific to a singular mathematical approach. 
Findings also extend the prior CFAs by identifying a potential sixth domain for 
consideration: lack of normal distress. This domain reflects the pathological reduction 
in the intensity or frequency of negative emotional experience. It has been 
demonstrated to be a hallmark feature of patients with deficit SZ who display primary 
and enduring negative symptoms37 and was part of the original descriptions of 
negative symptom pathology by early clinicians.1,2 The 2005 NIMH consensus 
conference26 indicated that there are at least 5 core negative symptom domains and 
listed the following 5 domains for consideration: anhedonia, avolition, asociality, 
blunted affect, and alogia. Lack of normal distress represents a strong candidate for a 
sixth domain to be considered.26 Future studies could use network analysis to test 
whether lack of normal distress is part of the negative symptom construct by 
constructing networks that include items from other symptom constructs (eg, hostility, 
depression, guilt, anxiety) and examining whether lack of normal distress falls into 
communities with negative symptom items, rather than communities related to these 
other negative emotion constructs. 
When viewed in relation to the 2 recent CFA papers,22,23 the current network analysis 
findings have important theoretical implications regarding the latent structure of 
negative symptoms. Recent trends toward conceptualizing negative symptoms in 
relation to 1- or 2-dimensional models, which primarily resulted from conclusions 
drawn from EFA studies,11–17 are not fully statistically justified. These models do not 
adequately capture the complexity of the negative symptom construct. The latent 
structure of negative symptoms is best conceptualized in relation to the 5 domains 
identified in the 2005 NIMH Consensus Development Conference: anhedonia, 
avolition, asociality, alogia, and blunted affect. A sixth domain, lack of normal distress, 
should also be considered if future studies support its separation from the other 5 
domains. Finding evidence for these 5 domains from a network perspective also 
extends the CFA findings, indicating that not only do items within these domains 
cluster together, but also that they have minimal interactions one another. This suggests 
that constructs (ie, items) within these domains are more likely to influence and be 
influenced by one another than they are from negative symptom constructs outside of 
that domain. Future studies should extend the current results by evaluating macroscopic 
properties, such as density and average shortest path length. These properties will offer 
insight into questions such as whether negative symptoms respond to treatment in 
patients whose networks are more vs less densely connected. It is conceivable for 
treatments to either benefit networks that are very densely connected (ie, because 
successful treatment of one domain will have a cascading effect on the others, which 
interact with the treated domain, resulting in global improvement) or not densely 
connected (ie, having an effect on one domain, which has little interaction with others 
and therefore does not result in interactions with other domains and global 
improvement). Microscopic properties, such as various measures of centrality, should 
also be examined because these will shed light onto whether any specific domains are 
more likely to influence others, and therefore the most appropriate targets for treatment. 
For example, Foussias and Remington52proposed that avolition is the most central 
negative symptom domain, influencing all other domains to become more severe when 
it is present (ie, when low motivation is present, patients are also less likely to seek out 
rewarding activities, social interactions, speak frequently, or express emotion). Such a 
hypothesis could be directly tested using network analysis. 
These findings also have several practical implications. First, based primarily on prior 
EFA results,11–17 the DSM-5 based its description of negative symptoms around the 
2 broad MAP and EXP dimensions. In future iterations of the DSM-5, a revision of 
these descriptions should be considered and the 5 consensus domains should be defined 
and considered individually. Second, the current focus on the 2 factors precludes the 
identification of pathophysiological mechanisms or treatment effects that are specific 
to the 5 domains. Indeed, there is some preliminary evidence for distinct 
pathophysiological correlates driving individual symptoms,31 suggesting that 
investigating mechanisms with greater granularity holds promise. The NIMH research 
domain criteria initiative has delineated neurobiological processes associated with 
aspects of “negative valence systems” relevant to lack of normal distress, “positive 
valence systems” relevant to avolition and anhedonia, and “social processes” that are 
relevant to asociality. Using such a framework, pathophysiology mechanisms 
associated with each domain should be evaluated to promote targeted treatment 
development. Finally, current procedures for scoring negative symptom scales as a 
singular total score or MAP/EXP dimension scores may be inadequate. Modern scales 
(CAINS, BNSS, SANS) should calculate scores for each of the 5 domains separately 
(for specific scoring suggestions see Strauss et al22). 
Finally, certain limitations should be considered. First, there was overlap between the 
2 current samples and those included in our prior CFA studies22,23. Second, although 
results were replicated across multiple samples and cultures, only a single negative 
symptom measure was evaluated. It is unclear whether these findings generalize to 
other measures. Third, our patients were in the chronic phase of illness, and it is unclear 
whether these results generalize to earlier phases. Fourth, it is unclear how certain 
clinical (eg, antipsychotics, functional outcome, diagnosis) and demographic (eg, sex) 
factors might influence clusters obtained. Future studies should replicate these findings 
in other datasets, using large representative samples of patients from multiple phases 
of illness, using multiple negative symptom scales that adequately cover the 5 domains 
according to modern conceptualizations (ie, BNSS, CAINS, SANS). Despite these 
limitations, findings add to a growing body of literature indicating that recent trends 
toward conceptualizing negative symptoms in relation to MAP and EXP factors do not 
adequately capture the complexity of the negative symptom construct; rather, negative 
symptoms appear to be best conceptualized in relation to the 5 consensus domains. It 
is possible that as negative symptom measurement evolves beyond clinical rating 
scales and tools with better temporal and spectral resolution become available (eg, 
ecological momentary assessment), these 5 domains will indeed be found to be even 
more complex and granular. 
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 Overview:  
Supplemental analyses were conducted to: 1) Determine whether alternate community detection methods (Fast 
Newman, Danon, and Martelot’s methods) produced different results than the Louvain method; 2) determine 
whether communities differed with item 4 (lack of normal distressed) removed. Analyses were conducted in 
both American and Italian samples.  
Fast Newman, Danon, and Martelot’s methods are greedy optimization methods that find the optimal 
community structure in the network by maximizing specific network criteria such as modularity. More 
specifically, these algorithms start with each node as a community and then aggregate/shift nodes until 
reaching the maximum value for the selected criteria. In this study, modularity is used as an evaluation criterion 
in the Fast Newman and Danon’s method, while two criteria of degree and modularity were used in the 
Martelot’s method (The implementation of these three methods were done in MATLAB). 
 
We have used the following statistical tests for examining the significance of identified community structure 
and each community within the identified community structure: 
• The Wilcoxon rank-sum test was used to check whether the internal degrees of nodes (sum of the edges 
connecting node to other nodes within their communities) are significantly different than their external degrees 
(sum of the edges connecting nodes to the nodes from other communities) in the identified community 
structure. The higher internal node degrees compared to the external degrees suggest the significance of the 
identified community structure (See Tables 2.A and 5. A for details).  
• The Wilcoxon rank-sum test was used to compare the internal/external degree distribution of the original 
community structure to the mean of the internal/external degree distribution of 50 randomly generated 
community structure (See Tables 2.A and 5. A for details).  
• The fraction of all the external degrees from each community to external degrees of each community in a 
random community structure was compared to test the significance of each community within the identified 
community structure. For that, first, a symmetric matrix is constructed where rows and columns refer to the 
detected communities, and each cell in the matrix is the fraction of all edges in the network that link nodes in 
community 𝑖 to nodes in community 𝑗. Next, this matrix is compared to the ones obtained from ones obtained 
from random community structures by subtracting the original matrix from the random ones divided by their 
standard deviation. The values greater than 1.96 (corresponding to p values less than 0.05) indicate that the 
community is significant (See Tables 2.B, 2.C, 5. B, and 5. C for details). 
 
Results indicated that the alternate network methods generally produced the same structure, with slight 
differences in whether item 2 (frequency of past week pleasure) fell within its own community or aligned with 
items 1 and 3 to form an aggregate anhedonia cluster. These differences across network methods were 
generally similar across cultures. 
A similar community structure was detected when item 4 was removed in both American and Italian samples. 
 
 
 
 
 
 
 
 
 
Table S1. Community Detection Results Using Louvain and Other Algorithms American Sample 
 
Tables S2A-C. Statistical tests Supporting Table S1 in American Sample 
A. Statistical Tests for Each Network Method in American Sample  
 
 
 
B. Louvain, Fast Newman, and Danon method Statistical Tests in American Sample 
                                                              Louvain, Fast  Newman, Danon and Martelot’s method 
Community 
# 1 2 3 4 5 6 7 
1 1.17876 0.996052 -0.949769 -0.631131 -0.622476 -2.6778 -1.82087 
2 0.996052 -1 -0.953234 0.0829847 2.075 -0.993875 -0.860517 
3 -0.949769 -0.953234 -1 -0.716123 -1.19718 -0.968029 0.245417 
4 -0.631131 0.0829847 -0.716123 1.57071 0.844838 -0.847698 -0.764256 
5 -0.622476 2.075 -1.19718 0.844838 4.53366 -0.83631 -0.675642 
6 -2.6778 -0.993875 -0.968029 -0.847698 -0.83631 4.04731 1.99956 
7 -1.82087 -0.860517 0.245417 -0.764256 -0.675642 1.99956 5.33681 
 
 
 
 
 
 
                Community 
Algorithm 
#1 #2 #3 #4 #5 #6 #7 
Louvain BNSS1, 
BNSS3 
BNSS
2 
BNSS4 BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Fast Newman BNSS1, 
BNSS3 
BNSS
2 
BNSS4 BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Danon BNSS1, 
BNSS3 
BNSS
2 
BNSS4 BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Martelot BNSS1, 
BNSS2 
BNSS3 
BNSS
4 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ 
 Indegree ( Original 
Net )vs. Extdegree ( 
Original Net ) 
Indegree  ( Original 
Net )vs.  Indegree  ( 
Random Net ) 
Extdegree  (Original 
Net)vs.  Extdegree  
(Random Net) 
                Stat 
Test 
Algorithm 
Statistics P-value Statistics P-value Statistics P-value 
Louvain 1.0 0.00187 5.0 0.0046 11.0 0.01577 
Fast Newman 1.0 0.00187 5.0 0.0046 11.0 0.01577 
Danon 1.0 0.00187 5.0 0.0046 11.0 0.01577 
Martelot 0.0 0.00147 12.0 0.01922 16.0 0.03918 
C. Fast Mo Statistical Tests in American Sample 
                                                              Martelot’s method 
Community 
# 1 2 3 4 5 6 
1 0.760416 -1.11809 -0.269925 0.956943 -2.51334 -2.09599 
2 -1.11809 -1 -0.75021 -1.0196 -0.908815 0.328606 
3 -0.269925 -0.75021 2.82119 0.930368 -0.713235 -0.809798 
4 0.956943 -1.0196 0.930368 2.88983 -0.996968 -0.888639 
5 -2.51334 -0.908815 -0.713235 -0.996968 3.52114 2.80095 
6 -2.09599 0.328606 -0.809798 -0.888639 2.80095 8.017 
 
 
Table S3. Community Detection Results Using Louvain and Other Algorithms-   WHITHOUT ITEM 4 in 
American Sample 
 
Table S4. Community Detection Results Using Louvain and Other Algorithms in Italian Sample 
 
 
 
 
 
 
                Community 
Algorithm 
#1 #2 #3 #4 #5 #6 #7 
Louvain BNSS1, 
BNSS3 
BNSS
2 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ 
Fast  Newman BNSS1, 
BNSS3 
BNSS
2 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ 
Danon BNSS1, 
BNSS3 
BNSS
2 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9 
 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Martelot BNSS1, 
BNSS2 
BNSS3 
BNSS
5, 
BNSS
6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ ------ 
                Community 
Algorithm 
#1 #2 #3 #4 #5 #6 #7 
Louvain BNSS1, 
BNSS2 
BNSS3 
BNSS
4 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ 
Fast Newman BNSS1, 
BNSS3 
BNSS
2 
BNSS4 BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Danon BNSS1, 
BNSS3 
BNSS
2 
BNSS4 BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Martelot BNSS1, 
BNSS2 
BNSS3 
BNSS
4 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ 
Table S5 A-C. Statistical tests Supporting Table S4 in Italian Sample 
A. Statistical Tests for Each Network Method in Italian Sample  
 
 
 
 
 
 
 
 
 
 
 
B. Louvain, Fast Mo Statistical Tests in Italian Sample 
  
                                                              Louvain, and Martelot’s method 
Community # 
1 2 3 4 5 6 
1 4.46491 -1.51115 -0.280871 -0.0365676 -1.00142 -1.25591 
2 -1.51115 -1 -1.22025 -1.47828 -2.05531 -1.53479 
3 -0.280871 -1.22025 2.24026 0.878647 -1.12711 -1.56105 
4 -0.036567 -1.47828 0.878647 2.17056 -0.307036 -1.08478 
5 -1.00142 -2.05531 -1.12711 -0.307036 4.08764 0.930824 
6 -1.25591 -1.53479 -1.56105 -1.08478 0.930824 3.06738 
 
C. Newman and Danon Statistical Tests in Italian Sample 
                                                              Fast  Newman, and Danon’s method  
Community # 
1 2 3 4 5 6 
 
7 
1 2.64044 4.41726 -1.02853 -0.407491 0.0395548 -0.803076 -1.35694 
2 4.41726 -1 -0.707993 0.0799086 -0.0844766 -0.471534 -1.06801 
3 -1.02853 -0.707993 -1 -1.08884 -0.874266 -1.56749 -1.65565 
4 -0.407491 0.0799086 -1.08884 1.25953 0.832278 -0.955088 -1.64719 
5 0.0395548 -0.0844766 -0.874266 0.832278 2.056 -0.114833 -1.28553 
6 -0.803076 -0.471534 -1.56749 -0.955088 -0.114833 3.5587 1.23789 
7 -1.35694 -1.06801 -1.65565 -1.64719 -1.28553 1.23789 2.4564 
 
 
 
 Indegree ( Original 
Net )vs. Extdegree ( 
Original Net ) 
Indegree  ( Original 
Net )vs.  Indegree  ( 
Random Net ) 
Extdegree  (Original 
Net)vs.  Extdegree  
(Random Net) 
                Stat 
Test 
Algorithm 
Statistics P-value Statistics P-value Statistics P-value 
Louvain 0.0 0.00147 3.0 0.00296 1.0 0.00187 
Fast Newman 0.0 0.00147 40.0 0.7007 1.0 0.00187 
Danon 0.0 0.00147   40.0    0.7007        1.0 0.00187 
Martelot 0.0 0.00147 3.0 0.00296 1.0 0.00187 
Table S 6. Community Detection Results Using Louvain and Other Algorithms-   WHITHOUT ITEM 4 in 
Italian Sample 
 
 
Table S7. BNSS Severity Scores 
 American 
Sample 
Italian 
Sample 
BNSS Item Severity Scores   
   1. Intensity of pleasurable activities 1.68(1.61) 2.85(1.56) 
   2.  Frequency of pleasurable activities 2.28(1.69) 2.95(1.59) 
   3. Intensity of future pleasure 1.01(1.54) 2.83(1.61) 
   4. Lack of normal distress 0.79(1.62) 2.44(1.60) 
   5. Asociality behavior 2.20(1.73) 3.31(1.59) 
   6. Asociality internal experience 1.66(1.72) 3.04(1.61) 
   7. Avolition behavior 2.40(1.80) 2.89(1.66) 
   8. Avolition internal experience 2.13(1.84) 2.81(1.62) 
   9. Facial expression 2.28(1.79) 2.72(1.68) 
   10. Vocal Expression 1.88(1.93) 2.64(1.78) 
   11. Body Gestures 1.99(1.83) 2.70(1.78) 
   12.  Quantity of speech 1.08(1.56) 2.27(1.77) 
   13. Spontaneous elaboration 1.26(1.67) 2.53(1.84) 
 
                Community 
Algorithm 
#1 #2 #3 #4 #5 #6 #7 
Louvain BNSS1, 
BNSS3 
BNSS
2 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Fast Newman BNSS1, 
BNSS3 
BNSS
2 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Danon BNSS1, 
BNSS3 
BNSS
2 
BNSS5, 
BNSS6 
BNSS7 
,BNSS8 
BNSS9, 
 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
Martelot BNSS1, 
BNSS2 
BNSS3 
BNSS
5, 
BNSS
6 
BNSS7 
,BNSS8 
BNSS9, 
BNSS10, 
BNSS11 
BNSS12, 
BNSS13 
------ ------ 
